SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Linda Kaplan who wrote (3503)4/20/1998 10:00:00 PM
From: Hank  Read Replies (2) of 7041
 
Linda,

People also tend to stay with the medications that work for them because Dr's are reluctant to change a patients meds once the symptoms have been successfully treated. Even if Vasomax made it to market, it will only be after every person with an interest has already tried Viagra. Only those that are unhappy with Viagra are likely to even try Vasomax. That will leave a small number of potential customers given Viagra's 70%-80% efficacy. Now add to that the fact that only 35% of those, at best, are likely to respond favorably to Vasomax and the market gets even smaller. IMO if a person doesn't respond to Viagra, they probably won't respond to Vasomax either even though the mechanisms are different. This is just my guess based on the significantly lower efficacy of Vasomax.

I might also add that once people get used to the idea that they have to take Viagra at least an hour in advance, the supposed 15 minute advantage that Vasomax offers will become less significant.

Hank
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News